Friday 6 November 2026 Export CRSP’s income statement to Excel — free account

CRISPR Therapeutics AG

CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.

Revenue: +1,325.1%
EPS: +1.55%
Free cash flow: −6.36%

Quarter to September 2026, against a year earlier

49.92 1.36 +2.80%

Follow CRSP

Alert me

Market cap: $4.7B
P/E: 0.0×
Fwd P/E: −11.8×
Dividend yield: —
F-score: 2/9
Altman Z: 7.04
Beneish M: n/a
Dividend safety: n/a

Overview

CRISPR Therapeutics AG (CRSP) P/B ratio

Alert me on P/B ratio

As of 6 November 2026, CRISPR Therapeutics AG (CRSP) trades at a P/B ratio of 2.9×. Over the past ten years it has ranged from 0.0× (December 2016) to 12.4× (March 2018); the current reading is higher than 49% of that period. That is above the Biotechnology industry median of 2.1× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/CRSP/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="CRISPR Therapeutics AG P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/CRSP/metrics/pb-ratio">CRISPR Therapeutics AG (CRSP) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	2.5×	42.79%
FY2024	1.7×	(38.17%)
FY2023	2.8×	63.54%
FY2022	1.7×	(29.14%)
FY2021	2.4×	(60.47%)
FY2020	6.1×	72.05%
FY2019	3.5×	0.93%
FY2018	3.5×	(34.91%)
FY2017	5.4×	353.20%
FY2016	1.2×	—

Period	P/B ratio	Change
Sep 2026	3.2×	7.74%
Jun 2026	3.0×	19.69%
Mar 2026	2.5×	2.62%
Dec 2025	2.5×	(20.55%)
38 more quarters	Free account

Against its own ten years

Low 0.0× High 12.4×

Ten-year median 2.9×

Current reading's percentile 48

Company	P/B ratio
CRSP CRISPR Therapeutics AG	2.9×
EWTX Edgewise Therapeutics, Inc. compare	3.0×
LEGN Legend Biotech Corporation Sponsored ADR compare	3.6×
DNTH Dianthus Therapeutics, Inc. compare	4.0×
DFTX Definium Therapeutics, Inc. compare	4.0×
MANE Veradermics Incorporated compare	6.9×
COGT Cogent Biosciences, Inc. compare	11.6×
ERAS Erasca, Inc. compare	12.3×
TVTX Travere Therapeutics, Inc. compare	207×
Biotechnology industry median	2.1×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

CRISPR Therapeutics AG (CRSP) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on CRSP

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on CRSP

Stockrow Weekly